Luke warm ICER backing on cost-effectiveness of new eye drug Luxturna

15 February 2018

The USA-based Institute for Clinical and Economic Review (ICER) on Wednesday released a Final Evidence Report and Report-at-a-Glance on Luxturna (voretigene neparvovec; VN) for the treatment of vision loss associated with RPE65-mediated retinal disease.

US biotech firm Spark Therapeutics’ (Nasdaq: ONCE) gained US approval for Luxturna in December 2017, making it the first treatment for this condition, but also raising significant concerns about its extremely high price.

Spark set the price of Luxturna at $425,000 per eye or $850,000 for both, which was however below the $500,000 per eye that observers had been predicting. Actual payment has been linked to short- and long-term performance of the therapy

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK